Drug intelligence / Profile preview

Kangfuxin lozenge

Development stage: Phase 2
Lead developer: Jingxin Pharmaceutical
Administration: Buccal

Overview

Kangfuxin lozenge is a Traditional Chinese Medicine (TCM) therapeutic developed by Zhejiang Jingxin Pharmaceutical, primarily indicated for the treatment of recurrent aphthous stomatitis (canker sores). The active component is an extract derived from the American cockroach (*Periplaneta americana*), which contains a complex mixture of amino acids, peptides, and polyols. This extract is known to facilitate wound healing by promoting the proliferation of granulation tissue, improving local microcirculation, and exerting anti-inflammatory and analgesic effects. The lozenge formulation is specifically designed for local application in the oral cavity, targeting the 'yin deficiency with excessive fire' pattern in TCM diagnosis.

Brand names: Kangfuxin
Other names: Kangfuxin HanpianPeriplaneta americana extract lozenge康复新含片

Beyond the preview

Go deeper on Kangfuxin lozenge.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kangfuxin lozenge.